94.2%
Data Quality Score
p=0.003
Primary Endpoint
2
Safety Signals
5
Novel Patterns
100%
DUA Compliant
186/248
Enrolled / Target
12
Active Sites
87.3%
Retention Rate
23
Open Queries
4.2d
Avg Query Resolution

Data Quality & Integrity

Validated
Data Completeness 96.8%
Schema Validation 100%
Cross-Table Integrity 99.2%
Date Logic Validation 98.5%
Range Check Compliance 97.1%

Population & Baseline Balance

Balanced
Characteristic Arm A Arm B Placebo p-value
Age (mean) 54.2 53.8 54.5 0.82
Female (%) 48.2% 51.3% 49.1% 0.76
Disease Duration (yrs) 6.4 6.1 6.6 0.58
Baseline Score 42.1 41.8 42.5 0.71

Primary Efficacy Analysis

In Progress
[Primary Endpoint Response Chart]
Forest Plot / KM Curve Placeholder
Endpoint Effect Size 95% CI p-value
Primary: Change from Baseline -4.2 pts [-6.1, -2.3] 0.003
Secondary: Responder Rate OR 2.1 [1.4, 3.2] 0.008

Safety & AE Signals

2 Signals
AE Category Treatment Placebo RR Flag
Headache 18.2% 12.1% 1.50 Monitor
Nausea 14.5% 8.3% 1.75 Monitor
Fatigue 9.2% 8.8% 1.05 OK
SAEs 2.4% 2.1% 1.14 OK

Subgroup & Responder Discovery

Exploratory
[Subgroup Forest Plot]
Interaction Analysis Placeholder
Key Findings (Exploratory):
  • Age ≥60: Enhanced response (Effect: -5.8 vs -3.2)
  • Biomarker+ subgroup: Higher responder rate (72% vs 48%)
  • Prior treatment naive: Stronger effect observed

⚠ Exploratory findings require independent validation

Sensitivity & Robustness

Pending
Analysis Result Status
Per-Protocol Analysis - Pending
Missing Data Sensitivity - Pending
Covariate Adjustment - Pending
Tipping Point Analysis - Pending

Benefit-Risk Synthesis

Pending Full Analysis

Benefits

  • Statistically significant primary endpoint
  • Clinically meaningful effect size
  • Strong responder rate advantage
  • Consistent across key subgroups

Risks

  • Increased headache incidence
  • Higher nausea rates
  • No new SAE signals identified
  • Manageable AE profile overall

Assessment

Preliminary B-R: Favorable

Awaiting full safety analysis and robustness confirmation before final synthesis.

Enrollment & Recruitment Tracking

On Track
Overall Enrollment 186/248 (75%)
312
Screened
59.6%
Screen-to-Enroll
8.2/wk
Enrollment Rate
[Enrollment Trend Chart - Cumulative vs Target]

Site Performance Metrics

2 Lagging
Site Enrolled Screen Fail Query Time Status
Boston Medical 28 18% 2.1d Top
Mayo Clinic 24 22% 2.8d Top
UCSF Medical 21 25% 3.2d Good
Johns Hopkins 8 45% 6.8d Lagging
Cleveland Clinic 5 52% 8.1d At Risk

Visit & Procedure Tracking

Active
Visit Completion Rate 94.2%
Lab Sample Collection 91.8%
ePRO Completion 88.5%
Visit Expected Completed Missing Overdue
Baseline 186 186 0 0
Week 4 172 168 4 2
Week 8 158 151 7 3
Week 12 142 128 14 5

Query Management

23 Open
247
Closed
23
Open
4
Overdue
4.2d
Avg Time
Query Type Open Avg Days Priority
Data Discrepancy 8 3.2 Medium
Missing Data 6 5.1 High
Protocol Deviation 5 2.8 High
AE Clarification 4 4.5 Medium

Safety Explorer Suite

Interactive Monitoring
📊
AE Explorer
Group & participant-level AE rates
📅
AE Timelines
Temporal AE visualization
📈
Safety Histogram
Parameter distributions
🔍
Outlier Explorer
Abnormal lab/vital detection
📈
Results Over Time
Longitudinal safety trends
⇄
Safety Shift Plot
Baseline vs post-treatment

Geographic Enrollment Distribution

12 Sites
[Geographic Heatmap - Site Enrollment by Region]
US Map with Site Performance Overlay
Northeast
68 pts (4 sites)
Midwest
52 pts (3 sites)
West
41 pts (3 sites)
South
25 pts (2 sites)

Dropout Prediction & Retention

ML Model
87.3%
Current Retention
84.1%
Predicted at EOT
At-Risk Patients (ML Predicted):
Patient ID Risk Score Top Risk Factor Action
FORE-001-142 0.78 Missed 2 visits
FORE-001-089 0.65 AE burden high
FORE-001-201 0.58 Travel distance
Model: XGBoost | AUC: 0.82 | Updated: 2025-01-22

Protocol Deviation Map & Trends

12 Active
[Deviation Heatmap by Site & Category]
Geographic concentration visualization
Deviation Type Count Trend
Visit Window 5 ↓ -2
Inclusion/Exclusion 3 ↔ 0
Dosing Error 2 ↑ +1
Consent Issue 2 ↓ -1

Wearable & ePRO Data

Real-Time
Device Compliance 82.4%
ePRO Daily Diary 78.9%
⏱
Activity: 6,842 steps/day
💖
HR: 72 bpm avg
💤
Sleep: 6.8 hrs avg

Predictive Analytics

AI/ML Models
Enrollment Forecast: Target completion by Week 18 (2 weeks ahead of schedule)
Site Alert: Cleveland Clinic may need intervention - predicted 40% below target
Safety Signal: Week 4-8 headache cluster detected - monitoring activated
Data Quality: 3 sites trending toward query backlog - proactive outreach recommended